Bioventix logo

BVXP - Bioventix Share Price

3115p -255.0  -7.6%

Last Trade - 22/10/19

Sector
Healthcare
Size
Small Cap
Market Cap £173.3m
Enterprise Value £167.9m
Revenue £8.82m
Position in Universe 825th / 1816
Bullish
Bearish
Unlock BVXP Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BVXP Revenue Unlock BVXP Revenue

Net Income

BVXP Net Income Unlock BVXP Revenue

Normalised EPS

BVXP Normalised EPS Unlock BVXP Revenue

PE Ratio Range

BVXP PE Ratio Range Unlock BVXP Revenue

Dividend Yield Range

BVXP Dividend Yield Range Unlock BVXP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BVXP EPS Forecasts Unlock BVXP Revenue
Profile Summary

Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors.

Directors
Last Annual June 30th, 2018
Last Interim December 31st, 2018
Incorporated October 7, 2003
Public Since April 29, 2014
No. of Shareholders: n/a
No. of Employees: 15
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (Full)
Shares in Issue 5,142,674
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BVXP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BVXP
Upcoming Events for BVXP
Thursday 31st October, 2019
Dividend For BVXP.L
Thursday 31st October, 2019
Dividend For BVXP.L
Friday 6th December, 2019 Estimate
Bioventix PLC Annual Shareholders Meeting
Similar to BVXP
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.